Advanced search
Publication Cover
Current Medical Research and Opinion Volume 26, 2010 - Issue 6
Submit an article Journal homepage
259
Views
12
CrossRef citations to date
0
Altmetric
Original Article

Observation of the treatment and outcomes of patients receiving chemotherapy for advanced NSCLC in Europe (ACTION study)

Helge G. Bischoff Thoraxklinik, Heidelberg, GermanyCorrespondence[email protected]
,
Ben van den Borne Catherina-ziekenhuis, Eindhoven, the Netherlands
,
Francisco L. Pimentel University of Aveiro, Aveiro, Portugal
,
Jorge Arellano Amgen Ltd, Uxbridge, UK; at the time of this study, Eli Lilly, Surrey, UK
,
Frank Langer Eli Lilly, Bad Homburg, Germany
,
Monika I. Leschinger Eli Lilly, Bad Homburg, Germany
&
Nicholas Thatcher The Christie NHS Foundation Trust, Manchester, UK
 show all
Pages 1461-1470 | Accepted 23 Mar 2010, Published online: 15 Apr 2010

References

  • Parkin DM, Pisani P, Ferlay J. Global cancer statistics. CA Cancer J Clin 1999;49:33-64
  • Non-small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995;311:899-909
  • Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993;342:19-21
  • Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer: results of a meta-analysis of the literature. Chest 1994;106:861-5
  • Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Nat Cancer Inst 2000;92:1074-80
  • Thatcher N, Anderson H, Betticher DC, et al. Symptomatic benefit from gemcitabine and other chemotherapy in advanced non-small cell lung cancer: changes in performance status and tumour-related symptoms. Anticancer Drugs 1995;6:39-48
  • Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs. BSC in inoperable non-small cell lung cancer – a randomized trial with quality of life as the primary outcome. Br J Cancer 2000;83:447-53
  • Clegg A, Scott DA, Hewitson P, et al. Clinical and cost effectiveness of palitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review. Thorax 2002;57:20-8
  • Cullen M, Szczepura A, Thomas M, et al. Taking ACTION to establish direct costs and outcomes of treating advanced non-small cell lung cancer in routine clinical practice. Lung Cancer 2003;43:113-15
  • Hollen PJ, Gralla RJ, Kris MG, et al. Quality of life assessment in individuals with lung cancer: testing the Lung Cancer Symptom Scale (LCSC). Eur J Cancer 1993;29:S51-8
  • Crawford J, Neidhart JA. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psychometric assessment of the Lung Cancer Symptom Scale. Cancer 2004;73:2087-98
  • Williams A. EuroQoL – a new facility for the measurement of health-related quality of life. Health Policy 1990;16:199-208
  • Oken, MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-55
  • Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-53
  • Everitt BS. Cluster Analysis, 3rd edn. London: Edward Arnold, 1993
  • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 2000;92:205-16
  • Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8
  • Sequist LV, Lynch TJ. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 2008;59:429-42
  • Baggstrom MQ, Socinski MA, Hensing TA, et al. Third generation chemotherapy regimens (3GR) improve survival over second generation regimens (2GR) in stage IIIB/IV non-small cell lung cancer (NSCLC): a meta-analysis of the published literature. Proc Am Soc Clin Oncol 2002;21:A1222

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.